Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drop showdown: which one is gentler on your tears?

NCT ID NCT07230548

Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested four different eye drops used in eye exams to see how they affect the thickness of the tear film in 20 healthy adults. Each person received all four drops on separate days, and their tear film was measured before and up to 4 hours after. The goal is to find which drops are least disruptive to the eye's natural moisture layer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oxybuprocaine and fluorescein eye drops
What this could lead to
If successful, this could help doctors choose eye drops that are gentler on the tear film, reducing irritation during exams.
What could go wrong
This is a small, early-phase study in healthy people, not patients. The findings may not apply to those with eye disease or long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

20 people

The number who actually took part.

Started

Jun 2020

Finished

Oct 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged at least 18 years * Written informed consent prior to study-related procedures * Normal ophthalmic findings * No use of eye drops including topical lubricants in the 4 weeks before screening Exclusion Criteria: * Participation in a clinical trial in the 3 weeks preceding the study * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Presence or history of a severe medical condition as judged by the clinical investigator * Intake of parasympathomimetic or anti-psychotic drugs * Wearing of contact lenses * Dry eye syndrome (Schirmer I test ≤10mm or TFBUT \<10 sec.) * Glaucoma in the medical history * Treatment with corticosteroids in the 4 weeks preceding the study * Topical treatment with any ophthalmic drug in the 4 weeks preceding the study * Ocular infection or clinically significant inflammation * Ocular surgery in the 3 months preceding the study * Sjögren's syndrome * Stevens-Johnson syndrome * History of allergic conjunctivitis * Pregnancy, planned pregnancy or lactating * Known hypersensitivity to any component of the study medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular surface disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular surface disease Tear film characteristics

Contacts and locations

Locations

  • Department of Clinical Pharmacology, Medical University of Vienna

    Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.